Anti-mesothelin chimeric antigen receptor T cell therapy - Shanghai Genechem

Drug Profile

Anti-mesothelin chimeric antigen receptor T cell therapy - Shanghai Genechem

Alternative Names: meso-CART - Shanghai Genechem; TAI-meso-CART - Shanghai Genechem

Latest Information Update: 17 May 2016

Price : $50

At a glance

  • Originator Shanghai Genechem
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Pancreatic cancer

Most Recent Events

  • 08 Mar 2016 Phase-I clinical trials in Pancreatic cancer (Second-line therapy or greater, Late-stage disease) in China (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top